Fortrea Holdings Inc(FTRE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 4:33 PM ET (Korea 11/3 06:33)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.74 | Insider Own | 1% | Shs Outstand | 96.5M | Perf Week | -15.99% |
| Market Cap | 1.93B | Forward P/E | 19 | EPS next Y | 23.62% | Insider Trans | -20.32% | Shs Float | 95.5M | Perf Month | 0.1% |
| Enterprise Value | 2.83B | PEG | 0.43 | EPS next Q | 0.2 | Inst Own | 104.52% | Short Float | 8.04% | Perf Quarter | 11.28% |
| Income | -0.07B | P/S | 0.72 | EPS this Y | 98.21% | Inst Trans | 1.05% | Short Ratio | 4.63 | Perf Half Y | 63.43% |
| Sales | 2.67B | P/B | 3.63 | EPS next 5Y | 44.67% | ROA | -2.51% | Short Interest | 7.68M | Perf YTD | 16.06% |
| Book/sh | 5.52 | P/C | 8.76 | EPS past 3/5Y | - -21.68% | ROE | -12.34% | 52W High | -23.47% ($26.16) | Perf Year | 91.4% |
| Cash/sh | 2.29 | P/FCF | 11.43 | Sales past 3/5Y | -4.19% 1.09% | ROIC | -4.25% | 52W Low | 134.15% ($8.55) | Perf 3Y | -32% |
| Dividend Est. | - | EV/EBITDA | 22.82 | EPS Y/Y TTM | 93.48% | Gross Margin | 17.05% | Volatility(W/M) | 8.19% 6.21% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 1.06 | Sales Y/Y TTM | -3.38% | Oper. Margin | 1.7% | ATR (14) | 1.47 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.97 | EPS Q/Q | 103.38% | Profit Margin | -2.58% | RSI (14) | 41.1 | Recom | 2.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.97 | Sales Q/Q | -1.4% | SMA20 | -10.31% ($22.32) | Beta | 1.86 | Target Price | $24.55 |
| Payout | - | Debt/Eq | 2.1 | Earnings | 2026/10/29 | SMA50 | -1.43% ($20.31) | Rel Volume | 1.06 | Prev Close | $21.29 |
| Employees | 14300 | LT Debt/Eq | 2.04 | EPS/Sales Surpr. | 28.97% 2.97% | SMA200 | 27.38% ($15.72) | Avg Volume(3M) | 1.66M | Price | $20.02 |
| IPO | 2023/6/16 | Option/Short | Yes/Yes | Trades | 15061 | Volume | 1,751,745 | Change | -5.97% |
🔬 This is a U.S. contract research organization (CRO) that provides clinical trial services. It designs and runs clinical trials on behalf of pharmaceutical and biotech companies, offering services across the full clinical development spectrum—from Phase I through late-stage trials—and has global clinical operations capabilities. The company is established as a clinical development services provider specializing in contract research.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded about as much as usual. That is 106% of its average volume.
FTRE keeps an operating profit but posts a net loss
Of every $100 in sales, $1.70 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +98.2% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $72. Peers typically go for $1,231.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be -32.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 104.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #99 of 597 in the industry
Based on market cap of $2B.
FAQ
What kind of company is FTRE?
FTRE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FTRE?
The market cap of FTRE is approximately $1.9B, ranking 2,064 within its sector.
What is the 52-week high and low for FTRE?
FTRE has recorded a 52-week high of $26.16 and a low of $8.55.
